Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$45.3 million.

  • Silence Therapeutics' Net Income towards Common Stockholders rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 24.27%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Net Income towards Common Stockholders is -$45.3 million, which was up 16.45% from -$54.2 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Net Income towards Common Stockholders peaked at -$41.7 million during FY2020, and registered a low of -$54.2 million during FY2023.
  • Over the past 3 years, Silence Therapeutics' median Net Income towards Common Stockholders value was -$50.1 million (recorded in 2022), while the average stood at -$49.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 66.94% in 2020, then increased by 16.45% in 2024.
  • Over the past 5 years, Silence Therapeutics' Net Income towards Common Stockholders (MRY) stood at -$41.7 million in 2020, then fell by 29.89% to -$54.2 million in 2021, then rose by 7.54% to -$50.1 million in 2022, then decreased by 8.19% to -$54.2 million in 2023, then rose by 16.45% to -$45.3 million in 2024.
  • Its last three reported values are -$45.3 million in FY2024, -$54.2 million for FY2023, and -$50.1 million during FY2022.